Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
McKinsey
AstraZeneca
Dow
Mallinckrodt

Last Updated: January 24, 2022

DrugPatentWatch Database Preview

Shionogi Inc Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for Shionogi Inc
International Patents:133
US Patents:10
Tradenames:6
Ingredients:6
NDAs:6

Drugs and US Patents for Shionogi Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shionogi Inc FETROJA cefiderocol sulfate tosylate POWDER;INTRAVENOUS 209445-001 Nov 14, 2019 RX Yes Yes 9,949,982 ⤷  Sign up for a Free Trial Y ⤷  Sign up for a Free Trial
Shionogi Inc MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes 9,427,402 ⤷  Sign up for a Free Trial Y ⤷  Sign up for a Free Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-003 Sep 9, 1993 DISCN No No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial
Shionogi Inc FETROJA cefiderocol sulfate tosylate POWDER;INTRAVENOUS 209445-001 Nov 14, 2019 RX Yes Yes 10,004,750 ⤷  Sign up for a Free Trial Y Y ⤷  Sign up for a Free Trial
Shionogi Inc FETROJA cefiderocol sulfate tosylate POWDER;INTRAVENOUS 209445-001 Nov 14, 2019 RX Yes Yes ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-002 Sep 9, 1993 DISCN No No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial
Shionogi Inc DORIBAX doripenem INJECTABLE;INTRAVENOUS 022106-001 Oct 12, 2007 DISCN Yes No 8,247,402 ⤷  Sign up for a Free Trial Y Y ⤷  Sign up for a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Shionogi Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shionogi Inc DORIBAX doripenem INJECTABLE;INTRAVENOUS 022106-001 Oct 12, 2007 8,247,402 ⤷  Sign up for a Free Trial
Shionogi Inc DORIBAX doripenem INJECTABLE;INTRAVENOUS 022106-002 Oct 5, 2010 8,247,402 ⤷  Sign up for a Free Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-001 Sep 9, 1993 4,631,286 ⤷  Sign up for a Free Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-004 Sep 9, 1993 4,631,286 ⤷  Sign up for a Free Trial
Shionogi Inc RYBIX ODT tramadol hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021693-001 May 5, 2005 5,464,632 ⤷  Sign up for a Free Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-003 Sep 9, 1993 4,631,286 ⤷  Sign up for a Free Trial
Shionogi Inc DORIBAX doripenem INJECTABLE;INTRAVENOUS 022106-002 Oct 5, 2010 5,317,016 ⤷  Sign up for a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SHIONOGI INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 250 mg/vial and 500 mg/vial ➤ Subscribe 2011-10-11
➤ Subscribe Lotion 5% ➤ Subscribe 2016-04-11

International Patents for Shionogi Inc Drugs

Country Patent Number Estimated Expiration
Taiwan I593690 ⤷  Sign up for a Free Trial
Japan WO2016035846 ⤷  Sign up for a Free Trial
World Intellectual Property Organization (WIPO) 2016035846 ⤷  Sign up for a Free Trial
Russian Federation 2010107169 ⤷  Sign up for a Free Trial
South Korea 101655961 ⤷  Sign up for a Free Trial
Spain 2599529 ⤷  Sign up for a Free Trial
South Korea 20130115257 ⤷  Sign up for a Free Trial
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Shionogi Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2184279 19C1043 France ⤷  Sign up for a Free Trial PRODUCT NAME: LUSUTROMBOPAG, UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI OU UN SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/18/1348 20190220
2184279 1990035-6 Sweden ⤷  Sign up for a Free Trial PRODUCT NAME: LUSUTROMBOPAG; REG. NO/DATE: EU/1/18/1348 20190220
0306228 SPC/GB01/002 United Kingdom ⤷  Sign up for a Free Trial PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
2184279 122019000065 Germany ⤷  Sign up for a Free Trial PRODUCT NAME: LUSUTROMBOPAG; REGISTRATION NO/DATE: EU/1/18/1348 20190218
2960244 43/2020 Austria ⤷  Sign up for a Free Trial PRODUCT NAME: CEFIDEROCOL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS; REGISTRATION NO/DATE: EU/1/20/1434 (MITTEILUNG) 20200424
2184279 2019/039 Ireland ⤷  Sign up for a Free Trial PRODUCT NAME: LUSUTROMBOPAG, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE THEREOF.; REGISTRATION NO/DATE: EU/1/18/1348 20190218
2960244 PA2020530 Lithuania ⤷  Sign up for a Free Trial PRODUCT NAME: CEFIDEROKOLAS, PASIRINKTINAI FARMACISKAI PRIIMTINOS DRUSKOS ARBA SOLVATO PAVIDALU; REGISTRATION NO/DATE: EU/1/20/1434 20200423
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts
Medtronic
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.